The
following table presents information about the Company’s reportable segments for the six and three months ended June 30, 2026 and
2025:
SCHEDULE OF INFORMATION RELATED TO OPERATIONS OF REPORTABLE OPERATING SEGMENTS
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Six
months ended | | |
Three
months ended | |
| | |
June
30 | | |
June
30 | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
| | |
| | |
| | |
| |
| Revenue from biotechnology activity | |
| - | | |
| - | | |
| - | | |
| - | |
| Cost related to biotechnology activity
(*) | |
| (434 | ) | |
| - | | |
| (310 | ) | |
| - | |
| Salaries and related expenses related to biotechnology
activity | |
| (582 | ) | |
| - | | |
| (325 | ) | |
| - | |
| Amortization of intangible
asset | |
| (202 | ) | |
| - | | |
| (102 | ) | |
| - | |
| Operating loss from Biotechnology
activity | |
| (1,218 | ) | |
| - | | |
| (737 | ) | |
| - | |
| | |
| | | |
| | | |
| | | |
| | |
| Revenue from renewable energy projects | |
| - | | |
| - | | |
| - | | |
| - | |
| Cost related to renewable
energy projects | |
| (19 | ) | |
| (130 | ) | |
| (15 | ) | |
| (59 | ) |
| Operating loss from renewable
energy projects | |
| (19 | ) | |
| (130 | ) | |
| (15 | ) | |
| (59 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Professional services | |
| (916 | ) | |
| (557 | ) | |
| (493 | ) | |
| (356 | ) |
| Share base compensation | |
| (1,399 | ) | |
| (2,029 | ) | |
| (250 | ) | |
| (1,988 | ) |
| Change in fair value of contingent consideration | |
| 203 | | |
| - | | |
| (139 | ) | |
| - | |
| Goodwill impairment | |
| (6,291 | ) | |
| - | | |
| - | | |
| - | |
| Depreciation | |
| (7 | ) | |
| - | | |
| (4 | ) | |
| - | |
| Other general and administrative
expenses | |
| (454 | ) | |
| (414 | ) | |
| (237 | ) | |
| (224 | ) |
| Total
Operating loss | |
| (10,101 | ) | |
| (3,130 | ) | |
| (1,875 | ) | |
| (2,627 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Interest of loans | |
| - | | |
| (77 | ) | |
| - | | |
| - | |
| Financing expenses, net | |
| (8,939 | ) | |
| (1,952 | ) | |
| (8,839 | ) | |
| (1,234 | ) |
| Other income | |
| 386 | | |
| - | | |
| - | | |
| - | |
| Changes in fair value
of investments measured under the fair value option | |
| 24 | | |
| (344 | ) | |
| (469 | ) | |
| (526 | ) |
| Income taxes | |
| 46 | | |
| - | | |
| 23 | | |
| - | |
| Net
loss | |
| (18,584 | ) | |
| (5,503 | ) | |
| (11,160 | ) | |
| (4,387 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| (*) | Costs
related to biotechnology activity primarily consist of subcontractors engaged in research and development activities |
|